ANNX — Annexon, Inc. Stock Price, Chart & AI Report

Positive May 11, 2026 • 14:00 UTC GlobeNewswire Inc. • Not Specified

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

The GBS|CIDP Foundation International is launching the 'GBS: 110 Years, 110 Stories' campaign to mark 110 years since the discovery of Guillain-Barré syndrome. The campaign will feature 110 patient stories in short videos to raise awareness about GBS and CIDP, rare neurological disorders. The foundation has partnered with Annexon Biosciences to promote the campaign throughout 2026, highlighting the need for advancements in patient care.

ANNX Guillain-Barré syndrome GBS CIDP awareness campaign neurological disorder patient stories rare disease

Sentiment note

Annexon is partnering with GBS|CIDP Foundation International to support awareness and research efforts for GBS patients. The partnership demonstrates the company's commitment to neuroinflammatory diseases and positions it as an active player in advancing therapies for rare neurological conditions, which aligns with its mission and could enhance brand reputation in the patient community.

Positive May 6, 2026 • 12:00 UTC GlobeNewswire Inc. • Not Specified

Annexon to Present at the Bank of America Securities Health Care Conference 2026

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on targeted immunotherapies for neuroinflammatory diseases, announced that its President and CEO Douglas Love will present at the Bank of America Securities Health Care Conference on May 13, 2026. The company is advancing therapies targeting C1q-driven neuroinflammation, with ARCHER II pivotal Phase 3 data in geographic atrophy expected in Q4 2026.

ANNX biopharmaceutical immunotherapies neuroinflammatory diseases complement pathway geographic atrophy clinical trial Phase 3 data

Sentiment note

The company is actively presenting at major healthcare conferences and advancing pipeline programs with anticipated pivotal Phase 3 data readouts. The focus on addressing a large patient population (10 million) with potential first-in-class therapy (vision-preserving treatment for geographic atrophy) demonstrates clinical progress and market opportunity.

Neutral Dec 17, 2025 • 00:31 UTC GlobeNewswire Inc. • Joyce Allaire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon, a biopharmaceutical company, granted a stock option to a new non-executive employee for 19,000 shares with a 4-year vesting schedule and an exercise price of $4.91 per share.

ANNX stock option employee compensation biopharmaceutical neuroinflammation

Sentiment note

The article describes a routine stock option grant to a new employee, which is a standard practice for tech and biotech companies and does not indicate significant positive or negative business developments

Neutral Nov 13, 2025 • 03:55 UTC GlobeNewswire Inc. • Annexon, Inc.

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Annexon, a biopharmaceutical company, announced a public offering of 25,096,153 shares of common stock and pre-funded warrants, expecting to raise $75 million to support its neuroinflammation research platform.

ANNX GS GSPA GSPC public offering neuroinflammation biopharmaceutical stock

Sentiment note

The company is raising capital through a public offering, which indicates a standard financial strategy for funding research and development without strong positive or negative implications

Positive Jul 24, 2025 • 11:00 UTC GlobeNewswire Inc. • Annexon, Inc.

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon completed enrollment for its Phase 3 ARCHER II trial of vonaprument, a potential treatment for dry age-related macular degeneration with geographic atrophy. The trial aims to demonstrate vision preservation and is expected to report topline data in the second half of 2026.

ANNX vonaprument dry AMD geographic atrophy clinical trial complement inhibition

Sentiment note

Company successfully enrolled its Phase 3 trial ahead of schedule, demonstrating strong progress in developing a potential first-in-kind treatment for dry AMD with geographic atrophy

Positive Jun 3, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight

The Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates, advancements in gene-targeting and disease-modifying therapies, and a robust clinical pipeline addressing critical unmet needs.

ANNX ALNY Huntington's disease clinical trials pipeline therapeutics dopamine receptor antagonists

Sentiment note

Annexon is one of the key companies working to develop Huntington's disease drugs, with the pipeline therapy ANX-005 in clinical trials.

Positive May 9, 2025 • 21:00 UTC GlobeNewswire Inc. • N/A

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

Annexon announced presentations at the 2025 PNS Meeting highlighting improved outcomes with its investigational therapy tanruprubart for the treatment of Guillain-Barré Syndrome (GBS), a rare autoimmune disease with no approved treatments.

ANNX Annexon tanruprubart Guillain-Barré Syndrome GBS PNS Meeting

Sentiment note

The article highlights Annexon's progress in developing tanruprubart, a potential first-in-kind therapy for the treatment of GBS, a rare and debilitating autoimmune disease. The company is presenting data at a major medical conference, indicating the advancement of this investigational therapy.

Positive Apr 3, 2025 • 22:18 UTC GlobeNewswire Inc. • N/A

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon, a biopharmaceutical company, is presenting data on its Phase 3 trial for ANX005, a potential treatment for Guillain-Barré Syndrome (GBS), at the AAN 2025 Annual Meeting. The company is also launching a disease education campaign to raise awareness about the impact of GBS.

ANNX Annexon Guillain-Barré Syndrome GBS ANX005 clinical research education

Sentiment note

The article highlights Annexon's leadership in advancing clinical research and education for Guillain-Barré Syndrome, including the presentation of positive Phase 3 data for its lead candidate ANX005 and the launch of a disease education campaign.

Positive Jan 7, 2025 • 13:00 UTC GlobeNewswire Inc. • N/A

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Annexon, Inc., a biopharmaceutical company, announced that its president and CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases.

ANNX Annexon biopharmaceutical neuroinflammatory diseases

Sentiment note

The article highlights Annexon's progress in developing novel therapies for neuroinflammatory diseases, which suggests the company is making advancements in its pipeline and has a positive outlook.

Positive Jul 11, 2024 • 22:10 UTC GlobeNewswire Inc. • N/A

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting - GlobeNewswire

Annexon announced it will present data from the Phase 2 ARCHER trial of its drug candidate ANX007 for the treatment of geographic atrophy, an advanced form of dry age-related macular degeneration. The data shows ANX007 provided statistically significant protection against vision loss and preservation of key retinal structures.

ANNX Annexon ANX007 geographic atrophy dry age-related macular degeneration Phase 2 ARCHER trial

Sentiment note

The article presents positive data from Annexon's Phase 2 trial of its drug candidate ANX007, which showed the drug provided significant protection against vision loss and preservation of retinal structures in patients with geographic atrophy.

Unknown Jun 28, 2024 • 13:40 UTC Zacks Investment Research • Zacks Equity Research

Are Medical Stocks Lagging Annexon (ANNX) This Year?

Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.

ANNX CCLD

Unknown Jun 27, 2024 • 13:55 UTC Zacks Investment Research • Zacks Equity Research

Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

ANNX